Cambria Pharmaceuticals

Cambria Pharmaceuticals Focuses on Discovering Innovative Treatments for Severe and Progressively Disabling Neurological Disorders. The company leverages recent discoveries in the genetic basis of these diseases to design new disease models and identify first-class disease-modifying compounds. Cambria advances its programs in ALS (Lou Gehrig's disease) and other serious neurological disorders through collaborations with academic institutions and patient-centered foundations.